Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Rawlins

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
BMJ (Clinical Research Ed.)|May 10, 2005
What's the evidence that NICE guidance has been implemented? More recent data on NICE implementation show different pictureMichael Rawlins, Andrew Dillon
British Journal of Clinical Pharmacology|May 24, 2014
Ron Mann: Pharmacoepidemiologist, 1928-2013Alasdair Breckenridge, Michael Rawlins
Drug Discovery Today|September 10, 2011
Pharmacogenetics and cost-effectiveness analysis: a two-way streetKalipso Chalkidou, Michael Rawlins
The Ulster Medical Journal|July 2, 2009
Helping to provide high quality care in primary careMichael Rawlins, Val Moore
Pharmacoepidemiology and Drug Safety|June 4, 2014
In memoriam: Ronald D. Mann, MD, FRCP, FRCGP, FFPM, FISPE, Professor Emeritus, Honorary Lifetime ISPE Fellow, 1928-2013: perspective from Medicines RegulatorsAlasdair Breckenridge, Michael Rawlins
The Health Service Journal|June 9, 2005
The HSJ debate. Quality-adjusted life years are too rigid a yardstick for the NHSNick Bosanquet, Michael Rawlins
Lancet (London, England)|October 22, 2008
Cost-effectiveness considerations at NICEMichael Rawlins, Andrew Dillon
Healthcare Quarterly (Toronto, Ont.)|May 28, 2014
Evidence and quality, practicalities and judgments: some experience from NICEAnthony Culyer, Michael Rawlins
BMJ (Clinical Research Ed.)|May 19, 2007
Commentary: NICE--setting clinical standardsGillian Leng, Michael Rawlins, Mercia Page
British Journal of Clinical Pharmacology|August 19, 2010
Pharmacoeconomics: NICE's approach to decision-makingMichael Rawlins, David Barnett, Andrew Stevens
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
BMJ (Clinical Research Ed.)|May 10, 2005
What's the evidence that NICE guidance has been implemented? More recent data on NICE implementation show different pictureMichael Rawlins, Andrew Dillon
British Journal of Clinical Pharmacology|May 24, 2014
Ron Mann: Pharmacoepidemiologist, 1928-2013Alasdair Breckenridge, Michael Rawlins
Drug Discovery Today|September 10, 2011
Pharmacogenetics and cost-effectiveness analysis: a two-way streetKalipso Chalkidou, Michael Rawlins
The Ulster Medical Journal|July 2, 2009
Helping to provide high quality care in primary careMichael Rawlins, Val Moore
Pharmacoepidemiology and Drug Safety|June 4, 2014
In memoriam: Ronald D. Mann, MD, FRCP, FRCGP, FFPM, FISPE, Professor Emeritus, Honorary Lifetime ISPE Fellow, 1928-2013: perspective from Medicines RegulatorsAlasdair Breckenridge, Michael Rawlins
The Health Service Journal|June 9, 2005
The HSJ debate. Quality-adjusted life years are too rigid a yardstick for the NHSNick Bosanquet, Michael Rawlins
Lancet (London, England)|October 22, 2008
Cost-effectiveness considerations at NICEMichael Rawlins, Andrew Dillon
Healthcare Quarterly (Toronto, Ont.)|May 28, 2014
Evidence and quality, practicalities and judgments: some experience from NICEAnthony Culyer, Michael Rawlins
BMJ (Clinical Research Ed.)|May 19, 2007
Commentary: NICE--setting clinical standardsGillian Leng, Michael Rawlins, Mercia Page
British Journal of Clinical Pharmacology|August 19, 2010
Pharmacoeconomics: NICE's approach to decision-makingMichael Rawlins, David Barnett, Andrew Stevens
Pageof 4